

RAMKHAMHAENG HOSPITAL

THAILAND / HEALTHCARE

RAM TB

BUY

UNCHANGED

In the pink of health

- ผู้ป่วยที่ปกติ และผู้ป่วยประกันสังคม (SSO) จะช่วยผลักดันการเติบโตภายในของ RAM และ VBR; การดำเนินงานของบริษัทร่วมจะพลิกฟื้น
- กำลังเตรียมเปิดโรงพยาบาลอีกหลายโรง พร้อมโอกาสในการซื้อกิจการเพิ่มเติม
- คงแนะนำซื้อหลังปรับราคาเป้าหมายขึ้นเป็น 56 บาท (DCF); หุ่นมีการซื้อขายในระดับการประเมินมูลค่าที่ถูกเพียง 23x ของค่า 2022E P/E (เทียบกับ 32x ของกลุ่มฯ)

คาดการณ์รายได้ของ RAM และ VBR จะสูงกว่าในปี 2019 อยู่ 12%/30%

เราคาดว่ารายได้จากโรงพยาบาลหลักของ RAM จะโต 8% y-y ในปี 2022 (คิดเป็นอัตราการเติบโต 12% เมื่อเทียบกับปี 2019) จากการฟื้นตัวของผู้ป่วยที่ไม่ได้เป็น Covid โดยเฉพาะอย่างยิ่งผู้ป่วยผ่าตัดที่ไม่เร่งด่วน และศูนย์การแพทย์เฉพาะทางใหม่ เช่น ศูนย์ปลูกถ่ายไตและศูนย์ผ่าตัดส่องกล้องเนื้ออกต่อมไธลสมอง แม้ว่ารายได้ของ Vibharam Group (VBR) น่าจะลดลง 24% y-y ในปี 2022 จากการชะลอตัวของรายได้ที่เกี่ยวข้องกับ Covid ในช่วง 2H22 ตัวเลขดังกล่าวน่าจะสูงกว่าในปี 2019 อยู่ 30% จากตัวเลขสมาชิกประกันสังคมจดทะเบียนที่เพิ่มขึ้นและกลยุทธ์ของ VBR ในการเปลี่ยนโรงพยาบาลที่ขาดทุนเป็นศูนย์การแพทย์เฉพาะทาง (เช่น ศูนย์มะเร็งที่ VBR Chaiprakarn)

ส่วนแบ่งรายได้ในปี 2022 จะกระโดดขึ้น 63% จากระดับก่อน Covid

เราเห็นแนวโน้มเชิงบวกสำหรับบริษัทร่วมของ RAM ประกอบด้วยสินแพทย์ THG และ VIBHA ซึ่งการดำเนินงานพลิกฟื้นและรายงานผลประกอบการที่ดีใน 4Q21 ซึ่งดีกว่าที่เราคาด เราคาดว่าส่วนแบ่งรายได้จะกระโดดเพิ่มเป็น 0.9 พัน ลบ. ในปี 2022 (เทียบกับ 0.5 พัน ลบ. ในปี 2019) ในภาพรวมเราคาดว่ากำไรปกติของ RAM จะกระโดดเพิ่ม 51% จาก 1.5 พัน ลบ. ในปี 2019 เป็น 2.2 พัน ลบ. ในปี 2022 แม้ว่าตัวเลขดังกล่าวอาจลดลง 45% y-y จากรายได้ Covid ที่ลดลง เราแนะนำให้นักลงทุนมองไปที่การเติบโตจากภายใน

5 โครงการสร้างใหม่จะช่วยเพิ่มปริมาณเตียงตามส่วนการลงทุนอีก 31%

นอกจากการเติบโตภายในที่ดีแล้ว เรายังคาดว่าบริษัท จะรายงานการเติบโตภายนอกอย่างมีนัยสำคัญใน 3 ปีข้างหน้า RAM วางแผนเปิด 5 โรงพยาบาลสร้างใหม่ ซึ่งน่าจะช่วยเพิ่มปริมาณเตียงตามส่วนการลงทุนอีก 31% เป็น 2,484 เตียงภายในปี 2025 นอกจากนี้ RAM ยังมีศักยภาพในการซื้อหุ้นเพิ่มในโรงพยาบาลหุ้นส่วน เนื่องจากบริษัท มีโรงพยาบาลในเครือข่ายมากถึง 30 แห่ง บัณฑิตดังกล่าวจะช่วยเพิ่มกำไรและให้มูลค่าเชิงยุทธศาสตร์แก่ RAM


ปรับเพิ่มประมาณการกำไรเพื่อสะท้อนแนวโน้มที่ดีขึ้นตลอดทั้งพอร์ต

เราปรับเพิ่มประมาณการกำไรปกติปี 2022-23 อีก 10-21% เพื่อสะท้อนแนวโน้มที่ดีขึ้นของโรงพยาบาลหลักของ RAM, VBR, และบริษัทร่วมต่าง ๆ นอกจากนี้เรายังตัดส่วนลดสภาพคล่อง 10% ออกเนื่องจากปริมาณการซื้อขายของหุ้นได้ปรับตัวดีขึ้นมาตั้งแต่เดือน ก.ย. 21 ซึ่งทำให้เราจึงปรับเพิ่มราคาเป้าหมายปี 2022 เป็น 56 บาท (DCF) ปัจจุบัน RAM มีการซื้อขายในระดับการประเมินมูลค่าที่ต่ำเพียง 23x ของค่า 2022E P/E (เทียบกับค่าเฉลี่ยของกลุ่มฯ ที่ 32x) และ 2.7x ของค่า 2022E P/BV (เทียบกับของกลุ่มฯ ที่ 4.7x)

TARGET PRICE	THB56.00
CLOSE	THB42.00
UP/DOWNSIDE	+33.3%
PRIOR TP	THB48.00
CHANGE IN TP	+16.7%
TP vs CONSENSUS	+16.7%

KEY STOCK DATA

YE Dec (THB m)	2021	2022E	2023E	2024E
Revenue	12,664	10,715	11,158	11,731
Net profit	4,193	2,226	2,241	2,451
EPS (THB)	3.49	1.85	1.87	2.04
vs Consensus (%)	-	(3.6)	15.1	22.9
EBITDA	4,162	3,141	3,251	3,479
Core net profit	4,070	2,226	2,241	2,451
Core EPS (THB)	3.39	1.85	1.87	2.04
Chg. In EPS est. (%)	nm	21.8	10.4	nm
EPS growth (%)	544.0	(45.3)	0.7	9.4
Core P/E (x)	12.4	22.6	22.5	20.6
Dividend yield (%)	1.8	2.2	2.2	2.4
EV/EBITDA (x)	15.7	20.3	19.5	17.8
Price/book (x)	2.9	2.7	2.6	2.4
Net debt/Equity (%)	37.6	27.9	24.8	17.2
ROE (%)	27.2	12.5	11.8	12.1



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	24.4	5.7	46.3
Relative to country (%)	23.7	3.3	37.0
Mkt cap (USD m)	1,515		
3m avg. daily turnover (USD m)	1.4		
Free float (%)	20		
Major shareholder	F&S 79 (23%)		
12m high/low (THB)	54.25/27.10		
Issued shares (m)	1,200.00		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA

teerapol.udo@fssia.com
+66 2611 3535

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากบทวิเคราะห์ของ FSSIA ฉบับวันที่ 1 เมษายน 2022

Investment thesis

RAM currently operates 17 hospitals with a capacity of more than 2,400 beds. We think the stock is undervalued due to its complicated structure and lack of trading liquidity. RAM split its par in 2021 and trading liquidity has improved since then.

RAM has diversified its portfolio both geographically and through its revenue mix. RAM has several hospital brands to capture patients from the middle-income to high-income segments.

RAM is in an expansion mode. Its organic growth should be driven by VBR, which is in a harvesting period after investing in greenfield hospitals. RAM also has five projects in the pipeline which should lift its capacity by almost 31% (based on equity beds) by 2025.


Company profile

RAM is a private hospital which opened in 1988. Currently, RAM operates 17 hospitals with a capacity of more than 2,000 beds. It is the second largest private hospital operator in Thailand in terms of registered beds.

www.ram-hosp.co.th

Principal activities (revenue, 2021)


- Cash patient - 69.8 %
- SSO - 12.4 %
- NHSO - 5.1 %
- Sales of medical equipment - 12.6 %



Source: Ramkhamhaeng Hospital

Major shareholders

- F&S 79 - 23.0 %
- Cypress Consolidated Healthcare - 20.0 %
- Chiangmai Ram Hospital - 7.2 %
- Synphaet - 6.6 %
- Vibhavadi Hospital PCL - 5.1 %



Source: Ramkhamhaeng Hospital

Catalysts

Key potential growth drivers include 1) an improving EBITDA margin led by new hospitals and a larger share of profits and dividend income from its subsidiaries; 2) more Social Security Office (SSO) registered members via VBR Group; and 3) benefitting from the economies of scale due to its large network.

Risks to our call

Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.

Event calendar

Date	Event
May 2022	1Q22 results announcement

Key assumptions

	2022E	2023E	2024E
Ramkhamhaeng revenue growth (y-y %)	8	6	5
Ramkhamhaeng EBITDA margin (%)	31	31	32
Subsidiary revenue growth (y-y %)	(23)	3	5
Subsidiary EBITDA margin (%)	29	28	29
Share income - Synphaet (THB m)	330	301	323
Share income - Sukhumvit (THB m)	69	73	76
Share income - Chiangmai Ram (THB m)	75	80	82
Share income - VIBHA (THB m)	132	136	152
Share income - THG (THB m)	225	167	175

Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in patient volume, we project 2023 earnings to rise by 3%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2023 earnings to rise by 5%, and vice versa, all else being equal.

Source: FSSIA estimates


RAM flagship continues to grow, led by non-Covid patients

RAM flagship's non-Covid patient revenue was 9% below the pre-Covid level in 2021. We expect it to jump by 16% y-y in 2022 to THB3.5b, exceeding the pre-Covid level by 6%. The revenue increase should be driven by the recovery of non-Covid patients, especially for elective surgery cases and at new specialised centres including the Kidney Transplant Center and Pituitary and Skull Base Center.

Meanwhile, we estimate Covid-related revenue to drop by c50% to THB215m in 2022, accounting for 6% of RAM flagship's medical treatments in 2022 (vs 14% in 2021). Combining Covid and non-Covid revenue, we estimate that RAM flagship's revenue in 2022 should exceed the pre-Covid level by 12%, relatively in line with management's guidance of 15%.


We expect revenue from sales of medical equipment to drop by 30% y-y in 2022, in line with the slowdown in Covid-related services. Overall, we expect RAM flagship's EBITDA margin to improve from 29% in 2021 to 30% in 2022, driven by higher revenue intensity from more complex cases. As a result, we expect 2022 EBITDA to be flat y-y at THB1.5b and exceed the pre-Covid level by 38%.

Exhibit 1: RAM flagship's non-Covid medical treatment revenue




Sources: RAM; FSSIA estimates

Exhibit 2: RAM flagship's Covid-related revenue




Sources: RAM; FSSIA estimates

Exhibit 3: Revenue from sales of medical equipment



Sources: RAM; FSSIA estimates

Exhibit 4: RAM flagship's EBITDA and EBITDA margin



Sources: RAM; FSSIA estimates

VBR should not be in the red again, even post Covid pandemic


VBR successfully turned its loss-making portfolio around to make a profit of cTHB1.9b and contribute cTHB0.9b in profit to RAM in 2021, driven mainly by strong Covid-related revenue which accounted for 50% of VBR’s revenue in 2021. We believe it should continue to record a profit, driven by better organic operations, especially Social Security Office (SSO) operations.

We forecast non-Covid patient revenue to jump by 16% in 2022, led by 10% y-y growth for SSO revenue and 23% growth for general cash patient revenue. We estimate that the SSO registered member base should increase by 6% to 487k in 2022. In addition, VBR plans to open a second specialised cancer centre at VBR Chaiprakarn after receiving good feedback for its first centre at VBR Amata Nakorn. This centre should benefit from the new “Cancer Anywhere Policy” and allow the hospital to permanently turn around, despite the slowdown of Covid-related revenue.

We estimate Covid-related revenue to be strong in 1H22 before gradually declining in 2H22, leading to Covid-related contributions dropping from 50% of VBR’s total revenue in 2021 to 23% in 2022. Combining Covid and non-Covid revenue, we expect VBR’s revenue to drop by 24% y-y to THB5.5b in 2022. However, it would still be higher by 30% vs the pre-Covid level; relatively in line with management’s guidance.


We also expect VBR’s EBITDA margin to narrow from 37% in 2021 to 30% in 2022 due to the slowdown of Covid-related services, but it should be much higher than it was in 2019 at 15% and sufficient for VBR to remain profitable going forward.

Exhibit 5: VBR’s non-Covid patient revenue




Sources: RAM; FSSIA estimate

Exhibit 6: VBR’s Covid-related revenue




Sources: RAM; FSSIA estimate

Exhibit 7: Number of SSO registered members



Sources: RAM; FSSIA estimate

Exhibit 8: VBR’s EBITDA margin



Sources: RAM; FSSIA estimate


Earnings and TP revisions

We revise up our revenue estimates by 9% and EBITDA margin assumptions by 2-3% over 2022-23 to reflect the better operational outlook of RAM's flagship hospital and VBR. We also raise our 2022-23 share income assumptions by 34-48% to reflect the strong operations and outlook of RAM's subsidiaries, especially Synphaet, THG and VIBHA, which posted better-than-expected share incomes in 4Q21.

Overall, we raise our 2022-23E core profit by 10-21%. We also remove a 10% liquidity discount factor given that the stock's trading volume has improved since Sep-21. Therefore, we raise our 2022 DCF-based TP to THB56/shr (8% WACC and 3% LTG), implying 30x 2022E P/E.


RAM is trading at a cheap valuation of only 23x 2022E P/E (vs peers' average of 32x) and 2.7x 2022E P/BV (vs peers' average of 4.7x).

Exhibit 9: RAM's revenue




Sources: RAM; FSSIA estimates

Exhibit 10: RAM's share income




Sources: RAM; FSSIA estimates

Exhibit 11: EBIT of THB3.1b – breakdown as of 2022E



Source: FSSIA estimates

Exhibit 12: RAM's core profit



Sources: RAM; FSSIA estimates

Exhibit 13: RAM – forecast revisions

	Current			Previous			Change		
	2022E	2023E	2024E*	2022E	2023E	2024E*	2022E	2023E	2024E*
	(THB b)	(THB b)	(THB b)	(THB b)	(THB b)	(THB b)	(%)	(%)	(%)
Revenue	10,715	11,158	11,731	9,788	10,273	n/a	9	9	n/a
EBITDA margin (%)	29.3	29.1	29.7	26.5	27.6	n/a	3	2	n/a
Core profit	2,226	2,241	2,451	1,841	2,040	n/a	21	10	n/a
Key assumptions									
RAM's flagship hospital revenue	3,757	3,982	4,181	3,517	3,693	n/a	7	8	n/a
Revenue from sales of medical equipment	1,110	1,166	1,224	911	938	n/a	22	24	n/a
Subsidiary hospital revenue	5,848	6,010	6,326	5,360	5,642	n/a	9	7	n/a
Share income	889	864	979	600	647	n/a	48	34	n/a

Note: *First time released; Change of items in percentage terms are represented in ppt change
Sources: RAM; FSSIA estimates

Exhibit 14: THG – forecast revisions

	Current			Previous			Change		
	2022E	2023E	2024E*	2022E	2023E	2024E*	2022E	2023E	2024E*
	(THB b)	(THB b)	(THB b)	(THB b)	(THB b)	(THB b)	(%)	(%)	(%)
OPD patient revenue	2.7	2.9	3.1	2.8	3.0	n/a	(3.0)	(3.0)	n/a
IPD patient revenue	2.9	3.2	3.5	3.7	3.7	n/a	(21.6)	(13.7)	n/a
Jin Wellbeing revenue	0.2	0.4	0.4	0.3	0.4	n/a	(24.9)	0.3	n/a
Revenue	9.6	9.8	10.2	9.0	9.7	n/a	7.3	0.7	n/a
EBITDA margin (%)	23.3	19.9	19.8	17.6	18.7	n/a	5.7	1.1	n/a
Core profit	0.9	0.6	0.7	0.5	0.6	n/a	98.4	(0.0)	n/a

Note: *First time released; Change of items in percentage terms are represented in ppt change
Sources: THG; FSSIA estimates

Exhibit 15: VIBHA – forecast revisions

	Current			Previous			Change		
	2022E	2023E	2024E*	2022E	2023E	2024E*	2022E	2023E	2024E*
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(%)	(%)	(%)
Revenue - Vibhavadi	2,893	2,950	3,130	2,893	2,950	n/a	-	-	n/a
Revenue - CMR	4,211	4,447	4,656	4,150	4,448	n/a	1.5	(0.0)	n/a
Total revenue	7,405	7,713	8,116	7,336	7,706	n/a	0.9	0.1	n/a
EBITDA margin (%)	20.7	21.9	22.8	21.8	23.0	n/a	(1.0)	(1.0)	n/a
Share income - Vibharam	295	205	226	121	126	n/a	173.5	79.1	n/a
Core profit	1,125	1,165	1,303	1,007	1,165	n/a	11.7	(0.0)	n/a

Note: *First time released; Change of items in percentage terms are represented in ppt change
Sources: VIBHA; FSSIA estimates

Exhibit 16: DCF-derived TP

Cost of equity assumptions	(%)		Cost of debt assumptions	(%)
Risk-free rate	3.0		Pre-tax cost of debt	3.5
Market risk premium	8.0		Marginal tax rate	20.0
Stock beta	1.0			
Cost of equity, Ke	10.7		Net cost of debt, Kd	2.8
Weight applied	70.0		Weight applied	30.0
WACC	8.3			
DCF valuation estimate	(THB b)	(THB/share)	Comments	
NPV	28.2	23.5	WACC 8.3%, Risk-free rate 3%, Risk premium 8%	
Terminal value	52.3	43.6	Terminal growth 3%	
Cash & liquid assets	2.2	1.8	At end-2022E	
Investments	0.0	0.0	At end-2022E	
Debt	(9.1)	(7.6)	At end-2022E	
Minorities	(6.3)	(5.3)	At end-2022E	
Residual ordinary equity	67.2	56.0		

Source: FSSIA estimates

Exhibit 17: Peer comparisons as of 31 Mar-22

Company	BBG	Rec	Share price			Market Cap (USD m)	PE		ROE		PBV		- EV/ EBITDA -	
			Current (LCY)	Target (LCY)	Upside (%)		22E (x)	23E (x)	22E (%)	23E (%)	22E (x)	23E (x)	22E (x)	23E (x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	25.00	29.00	16.0	11,943	39.4	31.7	11.8	13.9	4.6	4.3	20.0	16.9
Bumrungrad Hospital	BH TB	BUY	156.50	190.00	21.4	3,739	45.6	29.7	15.7	23.0	7.1	6.5	26.4	18.5
Bangkok Chain Hospital	BCH TB	BUY	20.60	28.50	38.3	1,544	14.1	26.0	27.4	14.4	3.8	3.7	8.7	13.3
Chularat Hospital	CHG TB	BUY	3.86	4.70	21.8	1,276	20.0	29.2	28.2	19.2	5.7	5.5	13.1	17.5
Praram 9 Hospital	PR9 TB	BUY	12.20	15.00	23.0	288	25.9	20.2	8.4	10.2	2.1	2.0	10.7	8.8
Thonburi Healthcare Group	THG TB	HOLD	83.25	32.50	(61.0)	2,121	78.4	113.2	9.8	6.7	7.6	7.6	35.7	40.9
Vibhavadi Medical Center	VIBHA TB	BUY	2.46	3.20	30.1	1,004	31.9	30.8	8.1	7.3	2.3	2.2	28.7	26.0
Ramkhamhaeng Hospital	RAM TB	BUY	42.00	56.00	33.3	1,515	22.6	22.5	12.5	11.8	2.7	2.6	20.3	19.5
Rajthanee Hospital	RJH TB	n/a	32.00	n/a	n/a	287	19.9	21.3	25.5	22.9	6.4	5.0	13.3	14.0
Ekachai Medical Care	EKH TB	n/a	7.35	n/a	n/a	132	25.3	24.3	15.6	14.3	5.1	3.6	14.5	13.4
Thailand average						23,850	32.3	34.9	16.3	14.4	4.7	4.3	19.1	18.9
Regional														
Ramsay Health Care	RHC AU	n/a	64.45	n/a	n/a	11,027	37.6	24.2	9.9	14.2	3.7	3.7	11.8	9.8
Ihh Healthcare Bhd	IHH SP	n/a	2.00	n/a	n/a	12,979	33.9	29.4	6.7	7.3	2.2	2.2	14.9	13.8
Ryman Healthcare	RYM NZ	n/a	9.17	n/a	n/a	3,169	19.9	14.7	7.5	8.9	1.4	1.4	19.6	16.7
Apollo Hospitals Enterprise	APHS IN	n/a	4,516	n/a	n/a	8,515	69.3	54.2	18.9	19.4	11.7	11.7	29.5	25.2
Kpj Healthcare Berhad	KPJ MK	n/a	1.01	n/a	n/a	1,052	30.9	23.2	6.6	8.6	1.9	1.9	12.1	10.9
Raffles Medical Group	RFMD SP	n/a	1.17	n/a	n/a	1,577	30.3	28.0	7.5	7.7	2.2	2.2	14.8	14.1
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,170	n/a	n/a	2,232	30.9	27.7	18.2	18.5	5.3	5.3	18.9	16.9
Aier Eye Hospital Group	300015 CH	n/a	31.55	n/a	n/a	27,376	56.5	44.4	22.0	23.4	11.9	11.9	33.9	26.8
Regional average						67,927	38.7	30.7	12.2	13.5	5.0	5.0	19.4	16.8
Overall average						91,776	35.1	33.0	14.5	14.0	4.9	4.6	19.3	17.9

Sources: Bloomberg; FSSIA estimates

Exhibit 18: Capacity summary

Group	No.	Hospital	RAM's stake (%)	No. of beds (no.)	No. of beds based on stake (no.)
Ramkhamhaeng Hospital	1	Ramkhamhaeng Hospital	100.0	486	486
Subsidiaries	2	Chaiphaphum Ram	78.0	60	47
	3	Mueng Loei Ram	77.7	100	78
Subsidiaries - Vibharam (VBR)	4	Pattanakarn	50.0	150	75
	5	Laemchabang	50.0	100	50
	6	Samutsakhon	50.0	100	50
	7	Nawamin	50.0	52	26
	8	Parkred	44.2	100	44
	9	Amatanakorn	37.6	100	38
	10	Chaiprakarn	49.6	100	50
	11	Mahaesak	25.9	132	34
	12	Phaetpanya	25.0	160	40
	13	Cancer Center Amatanakorn	18.8	10	2
		Total Ram and subsidiaries		1,650	1,019
Associates -operated directly	14	Chiang Mai Ram	42.9	200	86
	15	Phayao Ram	40.0	100	40
	16	Buriram Ram	36.1	90	32
	17	Sukhumvit	34.2	80	27
	18	Khonkaen Ram	16.4	300	49
		Total associates - operated directly		770	235
Associates -operated through Synphaet	19	Ramintra	28.4	380	108
	20	Theparak	23.0	120	28
	21	Lumlukka	28.4	120	34
	22	Srinakarin	14.2	100	14
	23	Kanchanaburi	26.3	100	26
	24	Serirak	14.3	141	20
		Total associates -operated through Synphaet		961	230
Partner hospitals	25	Vibhavadi (VIBHA)	9.2	1,282	118
	26	Thonburi (THG)	20.9	1,068	223
	27	Petcharat Hospital	17.9	100	18
	28	Rajthanee (RJH)	4.0	253	10
	29	Eak Udorn	9.3	350	33
	30	Chaophaya	6.8	200	14
		Total partner		3,253	416
		Grand Total existing beds		6,634	1,900
Projects in pipeline	31	Ramkhamhaeng 2 (Ram Nakra)	41.6	560	233
	32	Ramkhamhaeng 3 (Narathiwat Road)	100.0	210	210
	33	Nan Ram	25.7	141	36
	34	Vientiane Ram	70.0	150	105

	35	Thonburi Rangsit	40.0	250	100
		Total projects in pipeline		1,311	584

Sources: RAM; FSSIA estimates

Financial Statements

Ramkhamhaeng Hospital

Profit and Loss (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Revenue	7,822	12,664	10,715	11,158	11,731
Cost of goods sold	(5,508)	(7,127)	(6,296)	(6,585)	(6,894)
Gross profit	2,315	5,537	4,419	4,573	4,837
Other operating income	-	-	-	-	-
Operating costs	(1,260)	(1,375)	(1,278)	(1,322)	(1,358)
Operating EBITDA	1,055	4,162	3,141	3,251	3,479
Depreciation	(716)	(1,065)	(1,157)	(1,207)	(1,259)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	339	3,096	1,984	2,044	2,220
Net financing costs	(181)	(224)	(223)	(173)	(165)
Associates	120	2,469	889	864	979
Recurring non-operating income	460	2,850	1,245	1,237	1,369
Non-recurring items	0	122	0	0	0
Profit before tax	617	5,844	3,007	3,108	3,424
Tax	(148)	(468)	(381)	(426)	(489)
Profit after tax	469	5,376	2,626	2,681	2,935
Minority interests	163	(1,183)	(400)	(440)	(484)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	632	4,193	2,226	2,241	2,451
Non-recurring items & goodwill (net)	0	(122)	0	0	0
Recurring net profit	632	4,070	2,226	2,241	2,451
Per share (THB)					
Recurring EPS *	0.53	3.39	1.85	1.87	2.04
Reported EPS	0.53	3.49	1.85	1.87	2.04
DPS	0.72	0.76	0.93	0.93	1.02
Diluted shares (used to calculate per share data)	1,200	1,200	1,200	1,200	1,200
Growth					
Revenue (%)	75.9	61.9	(15.4)	4.1	5.1
Operating EBITDA (%)	(0.3)	294.4	(24.5)	3.5	7.0
Operating EBIT (%)	(61.1)	814.5	(35.9)	3.0	8.6
Recurring EPS (%)	(57.1)	544.0	(45.3)	0.7	9.4
Reported EPS (%)	(56.0)	563.3	(46.9)	0.7	9.4
Operating performance					
Gross margin inc. depreciation (%)	20.4	35.3	30.4	30.2	30.5
Gross margin of key business (%)	20.4	35.3	30.4	30.2	30.5
Operating EBITDA margin (%)	13.5	32.9	29.3	29.1	29.7
Operating EBIT margin (%)	4.3	24.4	18.5	18.3	18.9
Net margin (%)	8.1	32.1	20.8	20.1	20.9
Effective tax rate (%)	29.7	14.4	18.0	19.0	20.0
Dividend payout on recurring profit (%)	136.7	22.4	50.0	50.0	50.0
Interest cover (X)	4.4	26.6	14.5	19.0	21.8
Inventory days	45.6	38.7	41.3	37.9	37.8
Debtor days	43.1	54.7	82.3	75.6	71.9
Creditor days	27.0	25.0	25.1	23.0	23.0
Operating ROIC (%)	3.3	22.5	14.1	14.4	15.5
ROIC (%)	2.5	17.0	8.2	8.1	8.7
ROE (%)	5.0	27.2	12.5	11.8	12.1
ROA (%)	2.5	16.8	7.9	7.8	8.3
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)					
Cash patient	5,465	8,845	7,483	7,794	8,210
SSO	1,402	1,575	1,733	1,802	1,892
NHSO	196	649	389	397	405
Sales of medical equipment	760	1,595	1,110	1,166	1,224

Sources: Ramkhamhaeng Hospital; FSSIA estimates

Financial Statements

Ramkhamhaeng Hospital

Cash Flow (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Recurring net profit	632	4,070	2,226	2,241	2,451
Depreciation	716	1,065	1,157	1,207	1,259
Associates & minorities	-	-	-	-	-
Other non-cash items	697	1,167	400	440	484
Change in working capital	(663)	(199)	98	(1,039)	(12)
Cash flow from operations	1,383	6,104	3,881	2,850	4,182
Capex - maintenance	(8,952)	(944)	(643)	(669)	(704)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(1,327)	(4,833)	(285)	(395)	(395)
Other investments (net)	-	-	-	-	-
Cash flow from investing	(10,279)	(5,776)	(928)	(1,064)	(1,099)
Dividends paid	(810)	(812)	(912)	(1,113)	(1,121)
Equity finance	0	0	0	0	0
Debt finance	5,063	603	(800)	(600)	(300)
Other financing cash flows	4,247	392	(200)	(220)	(242)
Cash flow from financing	8,500	183	(1,912)	(1,933)	(1,663)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	(396)	510	1,041	(148)	1,420
Free cash flow to firm (FCFF)	(8,685.48)	566.89	3,209.42	2,022.62	3,308.36
Free cash flow to equity (FCFE)	413.45	1,322.26	1,952.97	965.07	2,540.96

Per share (THB)

FCFF per share	(7.24)	0.47	2.67	1.69	2.76
FCFE per share	0.34	1.10	1.63	0.80	2.12
Recurring cash flow per share	1.70	5.25	3.15	3.24	3.50

Balance Sheet (THB m) Year Ending Dec	2020	2021	2022E	2023E	2024E
Tangible fixed assets (gross)	18,063	19,277	19,920	20,590	21,294
Less: Accumulated depreciation	(7,958)	(9,294)	(10,452)	(11,659)	(12,918)
Tangible fixed assets (net)	10,105	9,983	9,469	8,931	8,376
Intangible fixed assets (net)	409	409	409	409	409
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	15,224	20,057	20,342	20,737	21,132
Cash & equivalents	616	1,126	2,167	2,020	3,440
A/C receivable	1,274	2,524	2,310	2,310	2,310
Inventories	754	756	668	698	731
Other current assets	708	373	315	1,006	1,062
Current assets	3,352	4,779	5,460	6,033	7,543
Other assets	188	197	197	197	197
Total assets	29,278	35,425	35,877	36,307	37,657
Common equity	12,804	17,179	18,492	19,621	20,951
Minorities etc.	5,103	6,129	6,329	6,549	6,791
Total shareholders' equity	17,906	23,308	24,821	26,170	27,742
Long term debt	3,137	4,351	4,051	3,751	3,751
Other long-term liabilities	980	404	404	404	404
Long-term liabilities	4,117	4,755	4,455	4,155	4,155
A/C payable	518	460	406	425	445
Short term debt	6,158	5,548	5,048	4,748	4,448
Other current liabilities	578	1,356	1,147	810	867
Current liabilities	7,255	7,363	6,601	5,983	5,760
Total liabilities and shareholders' equity	29,278	35,425	35,877	36,307	37,657
Net working capital	1,639	1,838	1,740	2,779	2,791
Invested capital	27,565	32,484	32,156	33,052	32,905

* Includes convertibles and preferred stock which is being treated as debt

Per share (THB)

Book value per share	10.67	14.32	15.41	16.35	17.46
Tangible book value per share	10.33	13.98	15.07	16.01	17.12

Financial strength

Net debt/equity (%)	48.5	37.6	27.9	24.8	17.2
Net debt/total assets (%)	29.6	24.8	19.3	17.8	12.6
Current ratio (x)	0.5	0.6	0.8	1.0	1.3
CF interest cover (x)	3.3	6.9	9.8	6.6	16.4

Valuation	2020	2021	2022E	2023E	2024E
Recurring P/E (x) *	79.7	12.4	22.6	22.5	20.6
Recurring P/E @ target price (x) *	106.3	16.5	30.2	30.0	27.4
Reported P/E (x)	79.7	12.0	22.6	22.5	20.6
Dividend yield (%)	1.7	1.8	2.2	2.2	2.4
Price/book (x)	3.9	2.9	2.7	2.6	2.4
Price/tangible book (x)	4.1	3.0	2.8	2.6	2.5
EV/EBITDA (x) **	60.8	15.7	20.3	19.5	17.8
EV/EBITDA @ target price (x) **	76.8	19.7	25.6	24.7	22.6
EV/invested capital (x)	2.3	2.0	2.0	1.9	1.9

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Ramkhamhaeng Hospital; FSSIA estimates

Corporate Governance report of Thai listed companies 2020

EXCELLENT LEVEL										
AAV	ADVANC	AF	AIRA	AKP	AKR	ALT	AMA	AMATA	AMATAV	ANAN
AOT	AP	ARIP	ARROW	ASP	BAFS	BANPU	BAY	BCP	BCPG	BDMS
BEC	BEM	BGRIM	BIZ	BKI	BLA	BOL	BPP	BRR	BTS	BWG
CENTEL	CFRESH	CHEWA	CHO	CIMBT	CK	CKP	CM	CNT	COL	COMAN
COTTO	CPALL	CPF	CPI	CPN	CSS	DELTA	DEMCO	DRT	DTAC	DTC
DV8	EA	EASTW	ECF	ECL	EGCO	EPG	ETE	FNS	FPI	FPT
FSMART	GBX	GC	GCAP	GEL	GFPT	GGC	GPSC	GRAMMY	GUNKUL	HANA
HARN	HMPRO	ICC	ICI	III	ILINK	INTUCH	IRPC	IVL	JKN	JSP
JWD	K	KBANK	KCE	KKP	KSL	KTB	KTC	LANNA	LH	LHFG
LIT	LPN	MAKRO	MALEE	MBK	MBKET	MC	MCOT	METCO	MFEC	MINT
MONO	MOONG	MSC	MTC	NCH	NCL	NEP	NKI	NOBLE	NSI	NVD
NYT	OISHI	ORI	OTO	PAP	PCSGH	PDJ	PG	PHOL	PLANB	PLANET
PLAT	PORT	PPS	PR9	PREB	PRG	PRM	PSH	PSL	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QTC	RATCH	RS	S	S & J	SAAM
SABINA	SAMART	SAMTEL	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SDC
SEAFCO	SEOIL	SE-ED	SELIC	SENA	SIRI	SIS	SITHAI	SMK	SMPC	SNC
SONIC	SORKON	SPALI	SPI	SPRC	SPVI	SSSC	SST	STA	SUSCO	SUTHA
SVI	SYMC	SYNTEC	TACC	TASCO	TCAP	TFMAMA	THANA	THANI	THCOM	THG
THIP	THRE	THREL	TIP	TIPCO	TISCO	TK	TKT	TTB	TMILL	TNDT
TNL	TOA	TOP	TPBI	TQM	TRC	TSC	TSR	TSTE	TSTH	TTA
TTCL	TTW	TU	TVD	TVI	TVO	TWPC	U	UAC	UBIS	UV
VGI	VIH	WACOAL	WAVE	WHA	WHAUP	WICE	WINNER	TRUE		

VERY GOOD LEVEL										
2S	ABM	ACE	ACG	ADB	AEC	AEONTS	AGE	AH	AHC	AIT
ALLA	AMANAHA	AMARIN	APCO	APCS	APURE	AQUA	ASAP	ASEFA	ASIA	ASIAN
ASIMAR	ASK	ASN	ATP30	AUCT	AWC	AYUD	B	BA	BAM	BBL
BFIT	BGC	BJC	BJCHI	BROOK	BTW	CBG	CEN	CGH	CHARAN	CHAYO
CHG	CHOTI	CHOW	CI	CIG	CMC	COLOR	COM7	CPL	CRC	CRD
CSC	CSP	CWT	DCC	DCON	DDD	DOD	DOHOME	EASON	EE	ERW
ESTAR	FE	FLOYD	FN	FORTH	FSS	FTE	FVC	GENCO	GJS	GL
GLAND	GLOBAL	GLOCON	GPI	GULF	GYT	HPT	HTC	ICN	IFS	ILM
IMH	INET	INSURE	IRC	IRCP	IT	ITD	ITEL	J	JAS	JCK
JCKH	JMART	JMT	KBS	KCAR	KGI	KIAT	KOOL	KTIS	KWC	KWM
L&E	LALIN	LDC	LHK	LOXLEY	LPH	LRH	LST	M	MACO	MAJOR
MBAX	MEGA	META	MFC	MGT	MILL	MITSIB	MK	MODERN	MTI	MVP
NETBAY	NEX	NINE	NTV	NWR	OCC	OGC	OSP	PATO	PB	PDG
PDI	PICO	PIMO	PJW	PL	PM	PPP	PRIN	PRINC	PSTC	PT
QLT	RCL	RICHY	RML	RPC	RWI	S11	SALEE	SAMCO	SANKO	SAPPE
SAWAD	SCI	SCP	SE	SEG	SFP	SGF	SHR	SIAM	SINGER	SKE
SKR	SKY	SMIT	SMT	SNP	SPA	SPC	SPCG	SR	SRICHA	SSC
SSF	STANLY	STI	STPI	SUC	SUN	SYNEX	T	TAE	TAKUNI	TBSP
TCC	TCMC	TEAM	TEAMG	TFG	TIGER	TITLE	TKN	TKS	TM	TMC
TMD	TMI	TMT	TNITY	TNP	TNR	TOG	TPA	TPAC	TPCORP	TPOLY
TPS	TRITN	TRT	TRU	TSE	TVT	TWP	UEC	UMI	UOBKH	UP
UPF	UPOIC	UT	UTP	UWC	VL	VNT	VPO	WIJK	WP	XO
YUASA	ZEN	ZIGA	ZMICO							

GOOD LEVEL										
7UP	A	ABICO	AJ	ALL	ALUCON	AMC	APP	ARIN	AS	AU
B52	BC	BCH	BEAUTY	BGT	BH	BIG	BKD	BLAND	BM	BR
BROCK	BSBM	BSM	BTNC	CAZ	CCP	CGD	CITY	CMAN	CMO	CMR
CPT	CPW	CRANE	CSR	D	EKH	EP	ESSO	FMT	GIFT	GREEN
GSC	GTB	HTECH	HUMAN	IHL	INOX	INSET	IP	JTS	JUBILE	KASET
KCM	KKC	KUMWEL	KUN	KWG	KYE	LEE	MATCH	MATI	M-CHAI	MCS
MDX	MJD	MM	MORE	NC	NDR	NER	NFC	NNCL	NPK	NUSA
OCEAN	PAF	PF	PK	PLE	PMTA	POST	PPM	PRAKIT	PRECHA	PRIME
PROUD	PTL	RBF	RCI	RJH	ROJNA	RP	RPH	RSP	SF	SFLEX
SGP	SISB	SKN	SLP	SMART	SOLAR	SPG	SQ	SSP	STARK	STC
SUPER	SVOA	TC	TCCC	THMUI	TIW	TNH	TOPP	TPCH	TPIPP	TPLAS
TTI	TYCN	UKEM	UMS	VCOM	VRANDA	WIN	WORK	WPH		

Description	Score Range
Excellent	90-100
Very Good	80-89
Good	70-79

Disclaimer:

The disclosure of the survey results of the Thai Institute of Directors Association (“IOD”) regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey results may be changed after that date. FSS International Investment Advisory Company Limited does not confirm nor certify the accuracy of such survey results.

* CGR scoring should be considered with news regarding wrong doing of the company or director or executive of the company such unfair practice on securities trading, fraud, and corruption SEC imposed a civil sanction against insider trading of director and executive; ** delisted

Source: Thai Institute of Directors Association (IOD); FSSIA's compilation

Anti-corruption Progress Indicator 2020

CERTIFIED										
2S	ADVANC	AI	AIE	AIRA	AKP	AMA	AMANAHA	AP	AQUA	ARROW
ASK	ASP	AYUD	B	BAFS	BANPU	BAY	BBL	BCH	BCP	BCPG
BGC	BGRIM	BJCHI	BKI	BLA	BPP	BROOK	BRR	BSBM	BTS	BWG
CEN	CENDEL	CFRESH	CGH	CHEWA	CHOTI	CHOW	CIG	CIMBT	CM	CMC
COL	COM7	CPALL	CPF	CPI	CPN	CSC	DCC	DELTA	DEMCO	DIMET
DRT	DTAC	DTC	EASTW	ECL	EGCO	FE	FNS	FPI	FPT	FSS
FTE	GBX	GC	GCAP	GEL	GFPT	GGC	GJS	GPSC	GSTEEL	GUNKUL
HANA	HARN	HMPRO	HTC	ICC	ICHI	IFS	INET	INSURE	INTUCH	IRPC
ITEL	IVL	K	KASET	KBANK	KBS	KCAR	KCE	KGI	KKP	KSL
KTB	KTC	KWC	L&E	LANNA	LHFG	LHK	LPN	LRH	M	MAKRO
MALEE	MBAX	MBK	MBKET	MC	MCOT	MFC	MFEC	MINT	MONO	MOONG
MPG	MSC	MTC	MTI	NBC	NEP	NINE	NKI	NMG	NNCL	NSI
NWR	OCC	OCEAN	OGC	ORI	PAP	PATO	PB	PCSGH	PDG	PDI
PDJ	PE	PG	PHOL	PL	PLANB	PLANET	PLAT	PM	PPP	PPPM
PPS	PREB	PRG	PRINC	PRM	PSH	PSL	PSTC	PT	PTG	PTT
PTTEP	PTTGC	PYLON	Q-CON	QH	QLT	QTC	RATCH	RML	RWI	S & J
SABINA	SAT	SC	SCB	SCC	SCCC	SCG	SCN	SEAOIL	SE-ED	SELIC
SENA	SGP	SIRI	SITHAI	SMIT	SMK	SMPC	SNC	SNP	SORKON	SPACK
SPC	SPI	SPRC	SRICHA	SSF	SSSC	SST	STA	SUSCO	SVI	SYNTEC
TAE	TAKUNI	TASCO	TBSP	TCAP	TCMC	TFG	TFI	TFMAMA	THANI	THCOM
THIP	THRE	THREL	TIP	TIPCO	TISCO	TKT	TTB	TMD	TMILL	TMT
TNITY	TNL	TNP	TNR	TOG	TOP	TPA	TPCORP	TPP	TRU	TSC
TSTH	TTCL	TU	TVD	TVI	TVO	TWPC	U	UBIS	UEC	UKEM
UOBKH	UWC	VGI	VIH	VNT	WACOAL	WHA	WHAUP	WICE	WIJK	XO
ZEN	TRUE									

DECLARED										
7UP	ABICO	AF	ALT	AMARIN	AMATA	AMATAV	ANAN	APURE	B52	BKD
BM	BROCK	BUI	CHO	CI	COTTO	DDD	EA	EFORL	EP	ERW
ESTAR	ETE	EVER	FSMART	GPI	ILINK	IRC	J	JKN	JMART	JMT
JSP	JTS	KWG	LDC	MAJOR	META	NCL	NOBLE	NOK	PK	PLE
ROJNA	SAAM	SAPPE	SCI	SE	SHANG	SINGER	SKR	SPALI	SSP	STANLY
SUPER	SYNEX	THAI	TKS	TOPP	TRITN	TTA	UPF	UV	WIN	ZIGA

Level	
Certified	This level indicates practical participation with thoroughly examination in relation to the recommended procedures from the audit committee or the SEC's certified auditor, being a certified member of Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) or already passed examination to ensure independence from external parties.
Declared	This level indicates determination to participate in the Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC)

Disclaimer:

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, FSS International Investment Advisory Company Limited does not confirm, verify, or certify the accuracy and completeness of the assessment results.

Note: Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of June 24, 2019) are categorised into: 1) companies that have declared their intention to join CAC, and; 2) companies certified by CAC.

Source: The Securities and Exchange Commission, Thailand; * FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSS makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSS has no intention to solicit investors to buy or sell any security in this report. In addition, FSS does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Ramkhamhaeng Hospital	RAM TB	THB 42.00	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.
Bangkok Dusit Medical Services	BDMS TB	THB 25.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bumrungrad Hospital	BH TB	THB 156.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Bangkok Chain Hospital	BCH TB	THB 20.60	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Chularat Hospital	CHG TB	THB 3.86	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Praram 9 Hospital	PR9 TB	THB 12.20	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Thonburi Healthcare Group	THG TB	THB 83.25	HOLD	Downside risks to our DCF-based target price include 1) weak patient volume following the economic slowdown; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected expenses from new hospitals. Upside risk is big-lot sales of Jin Wellbeing County units.
Vibhavadi Medical Center	VIBHA TB	THB 2.46	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited

FSSIA may incorporate the recommendations and target prices of companies currently covered by FSS Research into equity research reports, denoted by an 'FSS' before the recommendation. FSS Research is part of Finansia Syrus Securities Public Company Limited, which is the parent company of FSSIA.

All share prices are as at market close on 31-Mar-2022 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.